Business
Ventripoint to Issue Shares for Payment of Debenture Interest
(TheNewswire)   Toronto, Ontario – TheNewswire - December 17, 2025 –...
About this update from Ventripoint Diagnostics Ltd.
[{"type":"text","content":"Ventripoint to Issue Shares for Payment of Debenture Interest\n(TheNewswire)\n \n\nToronto, Ontario – TheNewswire - December 17, 2025 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”,\nTSXV:VPT) announces it will satisfy debenture\ninterest payment obligations with the issuance of common shares,\nsubject to TSX Venture Exchange (“TSXV”) approval.\nThe Corporation will issue an aggregate of 1,145,627 common shares\n(“Shares”) for the payment of an aggregate of $103,106.29 of\ninterest owing on certain outstanding Convertible Debentures issued by\nthe Corporation on May 10, 2024, June 28, 2024, September 20, 2024,\nJanuary 17, 2025, February 7, 2025, and March 21, 2025. The\nConvertible Debentures bear interest at the rate of 10% per annum,\npayable every 6 months. The Shares will be issued at a deemed price of\n$0.089, subject to the approval of TSXV, and are subject to a hold\nperiod of 4 months and one day. The issuance of the Shares will not\ncreate a control person of the Corporation.\n\n \n\nAbout Ventripoint Diagnostics\nLtd.\n\n\nVentripoint has become an\nindustry leader in the application of AI (Artificial Intelligence) to\nechocardiography. Ventripoint's VMS products are powered by its\nproprietary knowledge-based reconstruction technology, which is the\nresult of a decade of development and provides accurate volumetric\ncardiac measurements equivalent to MRI. This affordable, gold-standard\nalternative allows cardiologists greater confidence in the management\nof their patients. Providing better care to patients serves as a\nspringboard and basic standard for all of Ventripoint's products\nthat guide our future developments. In addition, VMS+ is versatile and\ncan be used with all ultrasound systems from any vendor supported by\nregulatory market approvals in the U.S., Europe and Canada.\n\n\nFor further information, please\ncontact:\n\n\nHugh MacNaught\n\n\[email protected]\n\n\n604-671-4201\n\n\nNeither the TSX Venture Exchange nor\nits Regulation Services Provider (as that term is defined in the\npolicies of the TSX Venture Exchange) accepts responsibility for the\nadequacy or accuracy of this news release.\n\n\nForward Looking Statements\n\n\nThis news release contains forward-looking statements\nand forward-...